---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-054628"
form_type: "8-K"
ticker: null
cik: "0001651407"
company_name: "Checkpoint Therapeutics, Inc."
filed_at: "2025-05-30T23:59:59+00:00"
generated_at: "2026-05-20T04:29:48.755675+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 1.0
calibrated_materiality_score: 1.0
confidence: "high"
source: SEC EDGAR
---

# Checkpoint Therapeutics completes acquisition by Sun Pharma for $4.10/share plus CVR

## Summary
- Merger closed May 30, 2025; Checkpoint becomes wholly owned subsidiary of Sun Pharma.
- Shareholders receive $4.10 cash per share plus non-tradable CVR (up to $0.70 contingent on EU regulatory milestones for cosibelimab).
- Common stock delisted from Nasdaq; Company intends to suspend SEC reporting obligations.
- All prior directors and officers resigned; Abhay Gandhi (President), Sudhir Valia (Director), Zvi Albert (CFO) appointed from Sun Pharma.
- Founders Agreement, Management Services Agreement, Board Advisory Services Agreement terminated at closing.

## SEC filing metadata
- accession: 0001104659-25-054628
- form_type: 8-K
- cik: 0001651407
- company_name: Checkpoint Therapeutics, Inc.
- filed_at: 2025-05-30T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 1.0
- calibrated_materiality_score: 1.0
- confidence: high
- sec_items: 1.02, 5.02, 2.01, 3.01, 3.03, 5.03, 5.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1651407/000110465925054628/0001104659-25-054628-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1651407/000110465925054628/tm2516558d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-054628
- JSON: https://secwatch.observer/filing/0001104659-25-054628.json
- Plain text: https://secwatch.observer/filing/0001104659-25-054628.txt

## Key facts
- Executive change
  Abhay Gandhi was appointed as Director at Checkpoint Therapeutics, Inc..
  - Action: became
  - Role: Director
  source text: (ii) Abhay Gandhi and Sudhir Valia, the directors of Merger Sub immediately prior to the Effective Time, became directors of the Company
  evidence_url: https://www.sec.gov/Archives/edgar/data/1651407/000110465925054628/0001104659-25-054628-index.htm
- Executive change
  Zvi Albert was appointed as Chief Financial Officer at Checkpoint Therapeutics, Inc..
  - Action: became
  - Role: Chief Financial Officer
  source text: (iv) Zvi Albert, the Chief Financial Officer of Merger Sub immediately prior to the Effective Time, became the Chief Financial Officer of the Company
  evidence_url: https://www.sec.gov/Archives/edgar/data/1651407/000110465925054628/0001104659-25-054628-index.htm
- Executive change
  Sudhir Valia was appointed as Director at Checkpoint Therapeutics, Inc..
  - Action: became
  - Role: Director
  source text: (ii) Abhay Gandhi and Sudhir Valia, the directors of Merger Sub immediately prior to the Effective Time, became directors of the Company
  evidence_url: https://www.sec.gov/Archives/edgar/data/1651407/000110465925054628/0001104659-25-054628-index.htm
- Executive change
  Abhay Gandhi was appointed as President at Checkpoint Therapeutics, Inc..
  - Action: became
  - Role: President
  source text: (iii) Abhay Gandhi, the President of Merger Sub immediately prior to the Effective Time, became the President of the Company
  evidence_url: https://www.sec.gov/Archives/edgar/data/1651407/000110465925054628/0001104659-25-054628-index.htm
- Governance Changes
  Checkpoint Therapeutics, Inc.: Amended and restated the bylaws in their entirety pursuant to the merger agreement.
  - Change: bylaw amendment
  source text: Pursuant to the Merger Agreement, as of the Effective Time, the Company’s bylaws, as in effect immediately prior to the Effective Time, were amended and restated in their entirety
  evidence_url: https://www.sec.gov/Archives/edgar/data/1651407/000110465925054628/0001104659-25-054628-index.htm
- M&A Transactions
  Checkpoint Therapeutics, Inc. underwent a change of control involving Sun Pharmaceutical Industries, Inc. for $4.10 in cash, without interest, and one non-tradable contingent value right (closed 2025-05-30).
  - Action: change of control
  - Counterparty: Sun Pharmaceutical Industries, Inc.
  - Consideration: $4.10 in cash, without interest, and one non-tradable contingent value right
  - Closing: 2025-05-30
  source text: Share (as defined in the Merger Agreement)) outstanding immediately prior to the Effective Time was canceled and ceased to exist and was converted into the right to receive (i) $4.10 in cash, without interest (the “ Common Cash Amount ”), and (ii) one non-tradable contingent value right (a “ CVR ”), which represents the right to receive a contingent cash
  evidence_url: https://www.sec.gov/Archives/edgar/data/1651407/000110465925054628/0001104659-25-054628-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.